NRP1 and acute lymphoblastic leukemia: Other markers, such as CD304, CD66c, and CD123, also demonstrated potential, with CD304 being overexpressed in 40–59% of BCP-ALL cases and CD123 showing strong prognostic value, particularly in cases with BCR-ABL1 and hyperdiploid karyotypes.